lymphoma

(redirected from Hodgkin lymphoma)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

lymphoma,

a cancer of the tissue of the lymphatic systemlymphatic system
, network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the veins of the circulatory system. The lymphatic system functions along with the circulatory system in absorbing nutrients from the small intestines.
..... Click the link for more information.
. There are two categories of lymphomas. One type is termed Hodgkin's diseaseHodgkin's disease,
a type of cancer of the lymphatic system. First identified in 1832 in England by Thomas Hodgkin, it is a type of malignant lymphoma. Incidence peaks in young adults and the elderly.
..... Click the link for more information.
, the other, non-Hodgkin's lymphoma (see lymphoma, non-Hodgkin'slymphoma, non-Hodgkin's,
any cancer of the lymphoid tissue (see lymphatic system) in which the Reed-Sternberg cells characteristic of Hodgkin's disease (the other category of lymphoma) are not present.
..... Click the link for more information.
). See also neoplasmneoplasm
or tumor,
tissue composed of cells that grow in an abnormal way. Normal tissue is growth-limited, i.e., cell reproduction is equal to cell death. Feedback controls limit cell division after a certain number of cells have developed, allowing for tissue repair
..... Click the link for more information.
.

lymphoma

[lim′fō·mə]
(medicine)
Any neoplasm, usually malignant, of the lymphoid tissues.
References in periodicals archive ?
With significant differences in each subtype's genetic profile and current treatment, there is reduced scope for the development of a targeted non hodgkin lymphoma market therapy with cross-subtype activity.
Evolution of classic Hodgkin lymphoma in correlation to changes in the lymphoid organ structure of vertebrates.
Unlike classical Hodgkin lymphoma, sclerosis between nodules is rare, but can occur in older lesions.
Prior studies have shown an association between a subset of classic Hodgkin lymphoma and Epstein-Barr virus (EBV) in several parts of the world.
A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
There is a high unmet need, both in Hodgkin lymphoma and non-Hodgkin lymphoma, which demands novel agents with improved efficacy and toxicity profiles.
Millennium announced in June 2011 that the European Medicines Agency accepted the filing of the Marketing Authorization Application for ADCETRIS for the treatment of relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic ALCL.
In June 2011, the European Medicines Agency accepted the filing of a Marketing Authorization Application (MAA) for ADCETRIS for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Seattle Genetics announced on May 2, 2011 that the FDA had accepted for filing two BLAs for brentuximab vedotin, including one for the treatment of relapsed or refractory Hodgkin lymphoma and one for the treatment of relapsed or refractory systemic ALCL.
These filings and priority review designations are an important step forward in our effort to bring brentuximab vedotin to the many relapsed and refractory Hodgkin lymphoma and systemic ALCL patients in need," said Clay B.
This is the first report of data from brentuximab vedotin in Hodgkin lymphoma patients who relapsed following allogeneic transplant.
Coverage of the Hodgkin Lymphoma pipeline on the basis of therapeutic class, route of administration and molecule type.